2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11D.01 A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX

EP.11D.01 A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX

Back to course

Pdf Summary

This phase II study, titled LungCadX, investigates the efficacy and safety of cadonilimab plus chemotherapy as a first-line treatment for patients with PD-L1-negative advanced non-small cell lung cancer (NSCLC). Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4 pathways, intended to enhance anti-tumor activity. The study enrolled 44 patients, administering cadonilimab with platinum-based chemotherapy (carboplatin combined with either paclitaxel or pemetrexed, depending on the NSCLC type) for up to four cycles. Post initial treatment, patients continued with cadonilimab monotherapy in squamous cases, and cadonilimab with pemetrexed in non-squamous cases.<br /><br />The primary endpoint focused on the 12-month progression-free survival (PFS) rate, assessed per RECIST 1.1. Secondary endpoints included objective response rate (ORR), overall survival (OS), duration of response (DoR), disease control rate (DCR), and safety assessments. The exploratory phase aimed to identify potential biomarkers from blood and tumor tissues.<br /><br />Initial results show promising clinical efficacy, with an investigator-assessed ORR of 66.7%, reaching 93.3% in squamous patients and 40.0% in non-squamous patients. The disease control rate was 100.0%. However, treatment-related adverse events (TRAEs) were noted in 61.4% of patients, with grade 3 adverse events in 34.1% of cases. Common TRAEs included leukopenia, neutropenia, anemia, and thrombocytopenia, but no treatment-related deaths were reported.<br /><br />The study concludes that cadonilimab plus chemotherapy demonstrates promising anti-tumor activity and manageable safety profiles, suggesting its potential as a treatment option for PD-L1-negative advanced NSCLC. Further analysis is ongoing to explore long-term outcomes and biomarker associations with treatment efficacy and patient prognosis.

Asset Subtitle

Li Wang

Meta Tag

Speaker Li Wang

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

LungCadX

cadonilimab

chemotherapy

PD-L1-negative

NSCLC

progression-free survival

objective response rate

treatment-related adverse events

biomarkers

anti-tumor activity